- ASH 2005: The IMF Takes You There
If you were not able to attend the 47th Annual Meeting of the American Society of Hematology (ASH), you have had to make do with brief updates of the activities. Until now. The IMF brings a wide array of ASH presenters direct to you. See and hear them explain their research via our ASH 2005 webcast
- Thalomid slows multiple myeloma, trial halted
Independent Data Monitoring Committee review determines that the Phase III pivotal trial (MM-003) meets the pre-established efficacy-stopping rule of p<0.0015 for the primary endpoint of time to disease progression. Treatment assignments for patients currently on the trials will be unblinded and those currently not on THALOMID will have the opportunity to add THALOMID to their dexamethasone regimen. (from Reuters) Read Celgene's Press Release.
- Revlimid Update
As most of you already know, Revlimid® has been approved by the Food and Drug Administration (FDA) for the indication of Myelodysplastic Syndrome (MDS). Celgene has filed clinical trial data with the Food and Drug Administration for review of Revlimid for the supplementary indication of multiple myeloma. Until the FDA reviews the myeloma data and makes a final decision on this supplemental indication, myeloma patients have access to Revlimid via the Expanded Access Program (EAP) and clinical trials. Please visit our web site at www.myeloma.org or call the IMF hotline (800-452-2873) for EAP site locations and clinical trial information.
- U.S. Cancer Death Rate Continues to Drop
Nation's cancer death rate continues to decline for most common forms, but, unfortunately, not for myeloma. (from ABC News)
- Updates from ASH Presentations
- Combination Therapy With Revlimid® And Velcade® Shows Promising Results
Early data was presented on the Phase I Revlimid + Velcade trial for relapsed and refractory myeloma. With 21 patients enrolled, the combination was safely combined and well tolerated; no maximum tolerated dose had been reached. The effects of the drugs in combination appear to be additive, with activity in 70% of the patients enrolled. This combination looks promising because there have been no reports of deep vein thrombosis, and because it is an approach that may be effective without the addition of steroids enrolled, the combination was safely combined and well tolerated; no maximum tolerated dose had been reached. The effects of the drugs in combination appear to be additive, with activity in 70% of the patients enrolled. This combination looks promising because there have been no reports of deep vein thrombosis, and because it is an approach that may be effective without the addition of steroids.
- Superiority of Alkeran®, Thalomid® Prednisone Regimen for Elderly Myeloma Patients Documented
Alkeran (melphalan), prednisone, Thalomid (thalidomide) regimen was superior to a standard Alkeran-prednisone regimen or a regimen of VAD (vincristine, doxorubicin, dexamethasone) followed by mobilization of stem cells with cyclophosphamide and Neupogen® (filgrastim) and tandem transplants with Alkeran (100 mg/m2).
[NOTE: Somehow we overlooked a misspelling of Thalomid in the blurb above when we published this Minute. Our apologies. The spelling above is correct.]
- Velcade® Promising as Initial Therapy for Multiple Myeloma
Velcade appears promising as initial treatment for patients with multiple myeloma, achieving high anti-cancer responses and allowing for successful subsequent stem cell transplants. Further studies are warranted to evaluate Velcade in the treatment of multiple myeloma.
- Many more presentations available as part of the IMF's ASH 2005 webcast.
WHAT'S NEW IN RESEARCH
(IMF Scientific Advisors are marked with asterisks)
- Prospective comparison of autologous stem cell transplantation followed by a dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
Frederic Garban, Michel Attal, Mauricette Michallet, Cyrille Hulin, Jean H Bourhis, Ibrahim Yakoub-Agha, Thierry Lamy, Gerald Marit, Frederic Maloisel, Christian Berthou, Mamoun Dib, Denis Caillot, Bernard dePrijck, Nicolas Ketterer, Jean-Luc Harousseau, Jean-Jacques Sotto, and Philippe Moreau
Blood published 5 January 2006, 10.1182/blood-2005-09-3869
- Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplant
Angela Dispenzieri, Martha Q Lacy, Jerry A Katzmann, S V Rajkumar*, Roshini S Abraham, Suzanne R Hayman, Shaji K Kumar, Raynell Clark, Robert A Kyle*, Mark R Litzow, David J Inwards, Stephen M Ansell, Ivana M Micallef, Luis F Porrata, Michelle A Elliott, Patrick B Johnston, Philip R Greipp, Thomas E Witzig, Steven R Zeldenrust, Stephen J Russell, Dennis Gastineau, and Morie A Gertz*
Blood published 5 January 2006, 10.1182/blood-2005-07-2922
- A new twist in myeloma treatment
Paul W. Sanders
Blood 2006;107 413-414
- IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells
Thomas Stromberg, Simon Ekman, Leonard Girnita, Lina Y. Dimberg, Olle Larsson, Magnus Axelson, Johan Lennartsson, Ulf Hellman, Kristina Carlson, Anders Osterborg, Karin Vanderkerken, Kenneth Nilsson, and Helena Jernberg-Wiklund
Blood 2006;107 669-678
- Myeloma wrecks Treg?
Qing Yi and Larry W. Kwak
Blood 2006;107 8-9
- Dysfunctional T regulatory cells in multiple myeloma
Rao H. Prabhala, Paola Neri, Jooeun E. Bae, Pierfrancesco Tassone, Masood A. Shammas, Charles K. Allam, John F. Daley, Dharminder Chauhan, Elizabeth Blanchard, Hemant S. Thatte, Kenneth C. Anderson*, and Nikhil C. Munshi
Blood 2006;107 301-304
- Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol
Philippe Moreau, Cyrille Hullin, Frederic Garban, Ibrahim Yakoub-Agha, Lotfi Benboubker, Michel Attal, Gerald Marit, Jean-Gabriel Fuzibet, Chantal Doyen, Laurent Voillat, Christian Berthou, Nicolas Ketterer, Philippe Casassus, Mathieu Monconduit, Mauricette Michallet, Albert Najman, Jean-Jacques Sotto, Regis Bataille*, and Jean-Luc Harousseau*, for the Intergroupe Francophone du Myelome group
Blood 2006;107 397-403
- Clinical implication of centrosome amplification in plasma cell neoplasm
Wee J Chng, Greg J Ahmann, Kim Henderson, Rafael Santana-Davila, Philip R Greipp, Morie A Gertz*, Martha Q Lacy, Angela Dispenzieri, Shaji Kumar, S V Rajkumar*, John A Lust, Robert A Kyle*, Steven R Zeldenrust, Suzanne R Hayman, and Rafael Fonseca*
Blood published 22 December 2005, 10.1182/blood-2005-09-3810
- Thalidomide derivative CC-4047 inhibits osteoclast formation by down regulation of PU.1
Gulsum Anderson, Margarete Gries, Noriyoshi Kurihara, Tadashi Honjo, Judy Anderson, Vera Donnenberg, Albert Donnenberg, Irene Ghobrial, Markus Y Mapara, David Stirling, David Roodman, and Suzanne Lentzsch
Blood published 22 December 2005, 10.1182/blood-2005-08-3450
If you would like more information about any clinical trial, you can call the IMF Hotline at 800-452-CURE. The Myeloma Matrix has a current list of all myeloma trials from pre-clinical to recently FDA approved. If you would like to browse trials currently open for enrollment, visit the Clinical Trials page of the IMF web site. Among the links, you will find EmergingMed, with whom the IMF has entered into a partnership to assist you in matching trials to your particular patient profile (i.e., stage of disease, previous treatment, how well you are able to carry out the activities of daily living, etc.) and by doing so, increase your chances of being eligible. You can also learn more about clinical trials by reviewing materials from the National Cancer Institute.
SHOP FOR THE IMF
GIVE UNTIL IT DOESN'T HURT! Shop at leading internet retailers (e-tailers) like Amazon.com, and they will donate a portion of your purchase to the IMF. You pay no more than you would normally, but part of your purchase is donated. Everything from clothing to computers to cruises. Buy it, and help the IMF at the same time.
To do this, you access their site via special links we have set up. For Amazon, it's http://amazon.myeloma.org instead of amazon.com. For office supplies from Staples, it is http://staples.myeloma.org and so on. These special links take you to your favorite retailers, and any purchase you make during that visit will be credited to the IMF.
Visit our Shop for the IMF page at http://shop.myeloma.org to see the complete list of popular etailers who will donate a portion of your purchase to the IMF. Giving has never been more painless!
Help Us Help Others...
As a non-profit organization, the IMF is completely dependent on the support of our members. Tax-deductible donations in honor of a friend or family member make great gifts and are a wonderful way to celebrate a special occasion. You can donate online or by calling the IMF at (800) 452-CURE. We sincerely thank you for your support.